close

Agreements

Date: 2021-07-15

Type of information: Construction of a production plant

Compound: new facility in Uttarakhand, India

Company: Recipharm (Sweden)

Therapeutic area: Technology - Services

Type agreement: construction of a production plant

Action mechanism:

Disease:

Details:

has announced investment into a new facility in Uttarakhand, India which will see its fill finish capacity increase to 1 billion sterile units per year. The facility will be constructed on a greenfield site near Dehradun in Uttarakhand and is a joint project between Recipharm and the Sobti family. The new site, which is designed for approval to supply the EU and US is now ready to begin production following approval from the local authorities. It will be delivering ampoules, vials filled with liquid and powder, lyophilised vials, dental cartridges and pre-filled syringes. The new facility is the latest development in Recipharm’s partnership with the Sobti family which began in 2019 when Recipharm invested in Nichepharm. The next step for the project will be to obtain authorisation from the European authorities. The facility will allow Recipharm to further increase its offering in sterile fill & finish service as it complements its three other sterile filling capabilities in France, Germany and Italy.
 
 

Financial terms:

Latest news:

Is general: Yes